Outlook Therapeutics
OTLK
54 hedge funds and large institutions have $4.32M invested in Outlook Therapeutics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 25 reducing their positions, and 19 closing their positions.
294% more call options, than puts
Call options by funds: $351K | Put options by funds: $89K
5.65% less ownership
Funds ownership: 17.8% → 12.15% (-5.7%)
18% less funds holding
Funds holding: 66 → 54 (-12)
52% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 25
55% less capital invested
Capital invested by funds: $9.56M → $4.32M (-$5.24M)
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$162K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$157K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$154K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$147K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.12M |
| 2 |
Morgan Stanley
New York
|
-$735K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
-$633K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$295K |
| 5 |
Squarepoint
New York
|
-$249K |
OTLK Hedge Fund Activity: Q3 2025 in Review
54 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2025, worth a combined $4.32M — down 55% from $9.56M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of OTLK and 7 opened new positions — a net loss of 12 holders — while 25 trimmed existing stakes and 12 added.
The largest buyer was Susquehanna International Group, adding an estimated $162K. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $1.12M.
- 54 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2025, down from 66 in Q2 2025.
- Funds reported $4.32M of Outlook Therapeutics stock for Q3 2025, down 55% quarter-over-quarter.
- 7 funds opened new Outlook Therapeutics positions in Q3 2025 and 19 closed out, a net change of -12 holders.
- The largest Outlook Therapeutics buyer in Q3 2025 was Susquehanna International Group, an estimated $162K added.
- The largest Outlook Therapeutics seller in Q3 2025 was Schonfeld Strategic Advisors, an estimated $1.12M sold.
Based on aggregated 13F filings for Q3 2025.